Key Takeaways & Executive Findings
- •• The original paper reported that overexpression of PTEN induces cell growth arrest and apoptosis in human breast cancer ZR-75-1 cells. • An error in Figure 4 of the original paper has been corrected; specifically, the fluorescence micrograph for the pBP-G129R-PTEN transfection was wrongly pasted. • The correction does not alter the results or conclusions of the original study. • The authors apologize for the inadvertent error and provide the correct figure for clarity.
Abstract
This is a corrigendum to the original article 'Overexpression of PTEN induces cell growth arrest and apoptosis in human breast cancer ZR-75-1 cells' published in Acta Biochim Biophys Sin 2007, 39(10): 745–750. The corrigendum corrects an inadvertent error in Figure 4, specifically the fluorescence micrographs of Hoechst 33258 stained ZR-75-1 breast cancer cells after transfection with pBP-G129R-PTEN (Figure 4C) was wrongly pasted. The correct Figure 4 is provided. This correction does not affect the results and conclusions of the original paper.
1. Introduction
This corrigendum addresses an inadvertent error in the original publication by Li et al. (2007) in Acta Biochim Biophys Sin. The original study investigated the effects of PTEN overexpression on cell growth and apoptosis in human breast cancer ZR-75-1 cells. The authors have identified a mistake in Figure 4, where the fluorescence micrograph for the pBP-G129R-PTEN transfection was incorrectly pasted. The correct figure is now provided to ensure the accuracy of the published data.
The correction is essential for maintaining the integrity of the scientific record. The authors confirm that the error does not affect the overall results or conclusions of the study. This corrigendum serves to rectify the visual representation of the experimental data and to provide readers with the correct information.
Loading authentic research manuscript (Pages 1–5)...
Xiangyong Li, Guanping Lin, Binhua Wu, Xin Zhou, Keyuan Zhou (2026). Corrigendum to: Overexpression of PTEN induces cell growth arrest and apoptosis in human breast cancer ZR-75-1 cells. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024244
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of this corrigendum?
This corrigendum corrects an error in Figure 4 of the original paper by Li et al. (2007) regarding the fluorescence micrograph for the pBP-G129R-PTEN transfection. The correct figure is provided to ensure the accuracy of the published data.
Does the correction affect the results or conclusions of the original study?
No, the correction does not affect the results or conclusions of the original study. The error was only in the visual representation of the data, and the authors confirm that the findings remain valid.
What was the original paper about?
The original paper investigated the overexpression of PTEN and its effects on cell growth arrest and apoptosis in human breast cancer ZR-75-1 cells.
What is the correct Figure 4?
The correct Figure 4 shows fluorescence micrographs of Hoechst 33258 stained ZR-75-1 breast cancer cells after transfection with plasmid pBP-wtPTEN or pBP-G129R-PTEN for 48 hours. It includes untreated group (A), pBP-wt-PTEN (B), and pBP-G129R-PTEN (C), with arrows pointing to apoptotic cells (400×).
Who are the authors of the original paper?
The authors of the original paper are Xiangyong Li, Guanping Lin, Binhua Wu, Xin Zhou, and Keyuan Zhou.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.